Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone.
John F Kokai-KunChenxiong LeKenneth TroutJulia L CopeNadim J AjamiAndrew J DegarSheila ConnellyPublished in: Infection and drug resistance (2020)
These findings demonstrated that ribaxamase reduced changes to the gut resistome subsequent to ceftriaxone administration and may help limit the emergence of AMR.